Literature DB >> 26055687

Risk factors for sepsis-related death in children and adolescents with hematologic and malignant diseases.

Hirozumi Sano1, Ryoji Kobayashi2, Akihiro Iguchi3, Daisuke Suzuki2, Kenji Kishimoto2, Kazue Yasuda2, Kunihiko Kobayashi2.   

Abstract

BACKGROUND: The aim of this study was to elucidate risk factors for mortality after developing sepsis in pediatric patients with hematologic and malignant disorders.
METHODS: A total of 90 patients (43 boys, 47 girls) with various hematologic and malignant diseases who experienced sepsis between June 2006 and March 2014 were enrolled. Clinical and laboratory features of 134 episodes of sepsis observed in the 90 patients were compared between those with and without sepsis-related death which was defined as death within 14 days after sepsis.
RESULTS: Age at hospitalization, sex, and type of underlying disease did not differ between patients with and without sepsis-related death. Sepsis episode-based univariate analysis identified patients with a history of relapse or in a refractory state of underlying disease (p<0.01), those with high C-reactive protein concentrations (≥50 mg/L) at the beginning of fever (p<0.01), those who had undergone hematopoietic stem cell transplantation (p<0.01), and those who were forced to change initial antibiotics (p = 0.02) because of being at high risk of sepsis-related death. The former two factors were further confirmed by multivariate analysis. More than half (52.9%) the isolates from sepsis-related death were Gram-positive cocci resistant to β-lactam antibiotics, but susceptible to vancomycin.
CONCLUSION: It was found that a history of relapse, a refractory state of underlying disease, and high C-reactive protein concentrations at the beginning of fever were significant risk factors for mortality after developing sepsis. Survival rate of patients with risk factors raised in this study might be improved by early introduction of vancomycin.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  C-reactive protein (CRP); refractory disease; relapse; risk factor; sepsis-related death; vancomycin

Mesh:

Year:  2015        PMID: 26055687     DOI: 10.1016/j.jmii.2015.04.002

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  5 in total

1.  The Prevalence of Risk Factors for the Development of Bacteraemia in Children.

Authors:  Sayed Yousef Mojtahedi; Aliakbar Rahbarimanesh; Leila Khedmat; Anahita Izadi
Journal:  Open Access Maced J Med Sci       Date:  2018-11-08

Review 2.  Antibiotic-Resistant Septicemia in Pediatric Oncology Patients Associated with Post-Therapeutic Neutropenic Fever.

Authors:  Rosalino Vázquez-López; Omar Rivero Rojas; Andrea Ibarra Moreno; José Erik Urrutia Favila; Adan Peña Barreto; Guadalupe Lizeth Ortega Ortuño; Jorge Andrés Abello Vaamonde; Ivanka Alejandra Aguilar Velazco; José Marcos Félix Castro; Sandra Georgina Solano-Gálvez; Tomás Barrientos Fortes; Juan Antonio González-Barrios
Journal:  Antibiotics (Basel)       Date:  2019-07-30

3.  Bacterial and Fungal Etiology of Sepsis in Children in the United States: Reconsidering Empiric Therapy.

Authors:  Andrew J Prout; Victor B Talisa; Joseph A Carcillo; Brooke K Decker; Sachin Yende
Journal:  Crit Care Med       Date:  2020-03       Impact factor: 7.598

4.  Machine Learning for Early Warning of Septic Shock in Children With Hematological Malignancies Accompanied by Fever or Neutropenia: A Single Center Retrospective Study.

Authors:  Long Xiang; Hansong Wang; Shujun Fan; Wenlan Zhang; Hua Lu; Bin Dong; Shijian Liu; Yiwei Chen; Ying Wang; Liebin Zhao; Lijun Fu
Journal:  Front Oncol       Date:  2021-06-15       Impact factor: 6.244

5.  Hospital acquired pneumonia risk factors in children with Acute Lymphoblastic Leukemia on chemotherapy.

Authors:  Anitha Marllyin Mairuhu; Mia Ratwita Andarsini; Retno Asih Setyoningrum; Andi Cahyadi; Maria Christina Shanty Larasati; I Dewa Gede Ugrasena; Bambang Permono; Satrio Budiman
Journal:  Heliyon       Date:  2021-06-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.